Delcath Systems/$DCTH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Delcath Systems
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Ticker
$DCTH
Sector
Primary listing
Employees
96
Headquarters
Website
Delcath Systems Metrics
BasicAdvanced
$315M
258.80
$0.03
0.41
-
Price and volume
Market cap
$315M
Beta
0.41
52-week high
$18.23
52-week low
$8.33
Average daily volume
1.1M
Financial strength
Current ratio
15.056
Quick ratio
12.815
Long term debt to equity
0.744
Total debt to equity
0.84
Profitability
EBITDA (TTM)
6.079
Gross margin (TTM)
86.29%
Net profit margin (TTM)
1.50%
Operating margin (TTM)
7.39%
Effective tax rate (TTM)
17.15%
Revenue per employee (TTM)
$830,000
Management effectiveness
Return on assets (TTM)
4.71%
Return on equity (TTM)
1.94%
Valuation
Price to earnings (TTM)
258.796
Price to revenue (TTM)
3.895
Price to book
2.75
Price to tangible book (TTM)
2.75
Price to free cash flow (TTM)
25.759
Free cash flow yield (TTM)
3.88%
Free cash flow per share (TTM)
0.347
Growth
Revenue change (TTM)
251.54%
Earnings per share change (TTM)
-102.65%
3-year revenue growth (CAGR)
166.87%
10-year revenue growth (CAGR)
47.81%
3-year earnings per share growth (CAGR)
-79.48%
What the Analysts think about Delcath Systems
Analyst ratings (Buy, Hold, Sell) for Delcath Systems stock.
Delcath Systems Financial Performance
Revenues and expenses
Delcath Systems Earnings Performance
Company profitability
Delcath Systems News
AllArticlesVideos
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire3 days ago
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
Business Wire4 days ago
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Delcath Systems stock?
Delcath Systems (DCTH) has a market cap of $315M as of November 17, 2025.
What is the P/E ratio for Delcath Systems stock?
The price to earnings (P/E) ratio for Delcath Systems (DCTH) stock is 258.8 as of November 17, 2025.
Does Delcath Systems stock pay dividends?
No, Delcath Systems (DCTH) stock does not pay dividends to its shareholders as of November 17, 2025.
When is the next Delcath Systems dividend payment date?
Delcath Systems (DCTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Delcath Systems?
Delcath Systems (DCTH) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.